CI

At a glance

ClinicalIndex Comparison Record
Phase 4Active· 40 target
Drug / intervention
Cladribinedrug
Likely dose
Cladribine 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04178005
NCT04178005Phase 4ActiveOn TrackUpdated 6mo ago
CompareCT.gov

Cladribine Tablets After Treatment With Natalizumab (CLADRINA)

University of Texas Southwestern Medical Center·interventional·Posted Nov 26, 2019·Updated Dec 8, 2025

In Brief

A Phase 4 clinical trial evaluating Cladribine for Multiple Sclerosis. Active but no longer recruiting, targeting 40 participants across 2 sites.

Detailed Summary

The purpose of this study is to generate hypotheses regarding the safety, efficacy, and immunological impact of cladribine tablets after treatment with natalizumab in patients with relapsing-remitting multiple sclerosis (RRMS) and active secondary progressive multiple sclerosis (active SPMS).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Sclerosis
CountriesUnited States
CollaboratorsEMD Serono

Timeline

Phase 4Active
20202021202220232024202520262027
First PostedNov 26, 2019
Enrollment StartFeb 19, 2020
Primary CompletionAug 30, 2026
Study CompletionDec 1, 2026
TodayJul 2, 2026
Enrollment to primary: 6.5 yearsPosted 6.6 years agoPrimary completion in 2 months

Interventions

Cladribinedrug

All study participants will receive treatment with cladribine 10 mg tablets at the recommended cumulative dose of 3.5 mg/kg, divided into 2 yearly treatment courses (1.75 mg/kg per treatment course). This regimen corresponds to the recommended dosage as per the USPI